Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

695 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH. Kummar S, et al. Among authors: tomaszewski j. Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/s00280-016-2998-6. Epub 2016 May 11. Cancer Chemother Pharmacol. 2016. PMID: 27169793 Free PMC article. Clinical Trial.
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
Speranza G, Anderson L, Chen AP, Do K, Eugeni M, Weil M, Rubinstein L, Majerova E, Collins J, Horneffer Y, Juwara L, Zlott J, Bishop R, Conley BA, Streicher H, Tomaszewski J, Doroshow JH, Kummar S. Speranza G, et al. Among authors: tomaszewski j. Invest New Drugs. 2018 Apr;36(2):230-239. doi: 10.1007/s10637-017-0495-3. Epub 2017 Aug 12. Invest New Drugs. 2018. PMID: 28808818 Free PMC article. Clinical Trial.
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH; National Cancer Institute Phase 0 Clinical Trials Team. Kinders RJ, et al. Among authors: tomaszewski j. Clin Cancer Res. 2010 Nov 15;16(22):5447-57. doi: 10.1158/1078-0432.CCR-09-3076. Epub 2010 Oct 5. Clin Cancer Res. 2010. PMID: 20924131 Free PMC article.
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y. Burton JH, et al. Among authors: tomaszewski j. Clin Cancer Res. 2018 Dec 1;24(23):5830-5840. doi: 10.1158/1078-0432.CCR-18-1498. Epub 2018 Jul 30. Clin Cancer Res. 2018. PMID: 30061364 Free PMC article.
Biotherapy module III. Interferons.
Gantz S, Tomaszewski JG, DeLaPena L, Molenda J, Bernato DL, Kryk J. Gantz S, et al. Among authors: tomaszewski jg. Cancer Nurs. 1995 Dec;18(6):479-91; quiz 492-4. Cancer Nurs. 1995. PMID: 8564945 No abstract available.
The immune system and cancer.
Tomaszewski JG, DeLaPena L, Gantz SB, Beranto DL, Woolery-Antill M, DiLorenzo K, Molenda J, Folts S. Tomaszewski JG, et al. Cancer Nurs. 1995 Aug;18(4):313-28; quiz 329-30. Cancer Nurs. 1995. PMID: 7664259 No abstract available.
695 results